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Boron-containing delocalised lipophilic cations for
the selective targeting of cancer cells†
Calabrese Gianpiero,*a Daou Anis,a Rova Aikaterini,b Tseligka Eirini,b
Vizirianakis S. Ioannis,b Fatouros G. Dimitriosc and Tsibouklis Johnd
To limit the incidence of relapse, cancer treatments must not promote the emergence of drug resistance
in tumour and cancer stem cells. Under the proviso that a therapeutic amount of boron is selectively deliv-
ered to cancer cells, Boron Neutron Capture Therapy (BNCT) may represent one approach that meets this
requirement. To this end, we report the synthesis and pharmacology of several chemical entities, based on
boron-rich carborane moieties that are functionalised with Delocalized Lipophilic Cations (DLCs), which
selectively target the mitochondria of tumour cells. The treatment of tumour and cancer stem cells (CSCs)
with such DLC-functionalized carboranes (DLC-carboranes) induces cell growth arrest that is both highly
cancer-cell-selective and permanent. Experiments involving cultures of normal and cancer cells show that
only normal cells exhibit recapitulation of their proliferation potential upon removal of the DLC-carborane
treatment. At the molecular level, the pharmacological effect of DLC-carboranes is exerted through activa-
tion of the p53/p21 axis.
Introduction
It is predicted that by the end of 2016 there will be 78 000
new cases of primary brain tumours; this figure includes
nearly 25 000 primary malignant and 53 000 non-malignant
brain tumours.1 Consequent to these levels of incidence,
around 17 000 people will lose their battle against primary
malignant and central nervous system (CNS) brain tumours.2
Glioblastomas, which are categorised by the World Health
Organization according to increasingly unfavourable progno-
sis as grades I to IV, account for 55% of all gliomas and 15%
of all primary brain tumours.3
Cancer cell initiation and progression represent complex
multifactorial processes that impede the efficacy and safe
clinical outcome of pharmacological interventions. Tumour
cells' heterogeneity and microenvironment present major
challenges at the clinical setting. Cancer treatment protocols
are determined by location, type and stage. Most commonly,
preliminary surgery is employed to remove as much tumour
tissue as possible, followed by radiotherapy and/or chemo-
therapy.4 Since glioblastomas possess a high metastasising
capability, relapse rates are very high.5 Recent experimental
evidence has identified cancer stem cells (CSCs) as a subpop-
ulation that exhibits distinct cellular and genomic character-
istics that render these cells capable of escaping
radiotherapy- and chemotherapy-induced cell death by
staying arrested over time at the G1/G0 cell growth phase,
which in turn allows them to re-enter the cell cycle under ap-
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propriate microenvironment conditions. This implies that re-
search efforts have to be focused on the design of anti-cancer
molecules, the therapeutic range of which includes CSCs.6–8
Owing to the capability of recently developed BNCT agents to
target cancer cells, including CSCs, both efficiently and selec-
tively, the clinical use of these agents may be characterized
by low incidence drug resistance profiles.9,10
Apart from the phenotypic distinctions, several differences
between mitochondria in normal and in tumour cells have
been observed, and some have been rationalized at the ge-
netic, molecular and biochemical levels.4,11,12 ATP synthesis
via oxidative phosphorylation displays an electrochemical
gradient that incorporates contributions from the pH gradi-
ent and the potential difference across the inner membrane
of mitochondria.13,14 The in vitro mitochondrial trans-
membrane potential of a healthy cell is in the range 180–200
mV; whereas, the corresponding in vivo potential is of the or-
der of 130–150 mV.15 The mitochondrial trans-membrane po-
tential of carcinoma cells is ca. 60 mV higher than that of ep-
ithelial cells.16 This difference makes mitochondria
promising targets for selective drug delivery. In addition, the
mitochondria of CSCs or tumour-initiating cells (TICs) ex-
hibit features – e.g. increased glycolytic metabolism, different
redox state regulation (mitochondrial membrane potential,
expression of apoptosis-related proteins) – that distinguish
them from the ordinary, more differentiated tumour cells.
These features may be exploited to guide the design of thera-
peutics that target cancer cells with a high degree of
specificity.17,18
Boron neutron capture therapy
(BNCT)
BNCT is a two-step chemo-radiotherapeutic technique (Fig. 1)
that involves the selective delivery of 10B-rich agents to tu-
mours and their subsequent irradiation with low-energy
neutrons.
The interaction of 10B with low-energy neutrons (i.e. the
capture reaction) results in nuclear fission that effects the se-
lective destruction of the host tumour cells. During this reac-
tion, energetic alpha particles possessing high linear energy
transfer (LET), low oxygen enhancement ratio and high rela-
tive biological effectiveness are produced. LET particles are
lethal but – because of their size, energy and short path
lengths (4.5–10 μm) – the effect is confined to the host cell.19
The predominant products of the 10B neutron capture reac-
tion are recoiling 7Li nuclei and α particles. It takes only a
few α particles, which are as lethal to hypoxic and oxygenated
cells as they are to non-proliferating cells, to kill a malignant
cell.20 If 10B is accumulated selectively in cancer cells and, as-
suming that in surrounding healthy tissue its concentration
does not exceed a certain critical value, the cytocidal effects
of the capture reaction are limited to malignant cells. Inevita-
ble capture reactions involving 1H and 14N from normal tis-
sue, which respectively produce γ rays and protons, are of lit-
tle relevance since the corresponding thermal-neutron-
capture cross-sections for these nuclei are too small to induce
marked complications during BNCT.21
BNCT has been investigated for use in the treatment of
glioblastoma multiforme (GBM),22 a malignancy with a cur-
rent mean survival time of <12 months.23 BNCT offers prom-
ise in GBM, but significant research effort is required before
the many performance requirements for successful treatment
are met,24 including the synthesis of 10B-enriched com-
pounds with very low inherent toxicity and integration of the
selective targeting strategy into the molecular design, such
that therapeutically useful concentrations (>109) of 10B
atoms/tumour cells are achieved while a tumour/blood con-
centration ratio >5 : 1 and a tumour/normal tissue concentra-
tion ratio >3 : 1 are maintained throughout the neutron cap-
ture stage of the treatment.
The multitude of performance demands that 10B-
containing drugs need to satisfy before they can be used in
the clinic is reflected by the very small number of 10B com-
pounds that have reached this stage: para-
boronophenylalanine (BPA) and sodium mercapto-
undecahydrododecaborate (BSH), which respectively incorpo-
rate 1 and 12 boron atoms in their molecular structures. Fol-
lowing an early attempt by Pitochelli and Hawthorne25 and
fuelled by the data of clinical trials conducted by Hatanaka26
in Japan, polyhedral boranes have become the materials of
choice for the delivery of 10B-rich moieties to cancer cells.
Among the common polyhedral boron agents, the neutral li-
pophilic icosahedral dicarba-closo-dodecarboranes (C2B10H12;
commonly referred to as carboranes), which also exist as
ortho-, meta- and para-isomers, are of particular interest not
only because of their high 10B content, good catabolic stabil-
ity and low toxicity, but also because of their amenability to
chemical functionalisation.21 The base-induced removal of
one boron atom from the icosahedral cage transforms the
Fig. 1 BNCT steps: the selective delivery of 10B-containing drugs to tumour cells is followed by irradiation with thermal neutrons (1n) to initiate
the destruction of cancer cells and to allow tissue repair.
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lipophilic closo-carborane into the corresponding nido-
carborane, which is more hydrophilic and hence more com-
patible with water-based systems.
Mitochondrial targeting
Integral to the performance requirements for BNCT is the
molecular design of boron compounds that are capable of
targeting intra-cellular organelles. Neoplastic cells are charac-
terized by high metabolic activity, which renders the design
of therapeutic agents that target the cellular organelles possi-
ble, of both dividing and non-dividing cancer cells.27 Since
the negative-inside transmembrane potential of mitochondria
(130–150 mV) is far greater than that of any other organelle,
functionalisation with DLC moieties represents a means of
imparting mitochondrial targeting specificity to carboranes.28
Some examples29,30,31,32 of DLCs that have been shown to ac-
cumulate preferentially in malignant cells are presented in
Fig. 2.
As the name implies, all DLCs are amphiphilic cationic
compounds in which the positive charge is delocalized over
an extensive π electron system. Their lipophilic nature and
the delocalization of the positive charge over a large area act
cooperatively to reduce the free energy change when DLCs
diffuse through lipid membranes, such as those of mitochon-
dria. Driven by the mitochondrial membrane potential, the
accumulation of DLCs may be described by the Nernst
equation:
ΔΨ(mV) = 61.5 log10{[cation]in/[cation]out}
Since the mitochondrial membrane potential of carci-
noma cells is ca. 60 mV greater than that of normal epithelial
cells,16 one consequence of the Nernstian relationship is that
there is a ten-fold increase in the propensity of DLCs to accu-
mulate within the mitochondria of such cells.33 This process
is further assisted by the plasma membrane potential (typi-
cally 30–60 mV; negative inside), which promotes the in-
creased accumulation of cations into carcinoma cells prior to
their localisation into mitochondria. The synergistic effect re-
sults in 90–95% of the available intracellular cations becom-
ing localised at mitochondrial sites.34
DLCs, often termed mitochondriotropics,35,36 are used ex-
tensively in the visualisation of mitochondria and also in the
estimation of mitochondrial activity.37,38 The use of these
materials in diagnosis is constrained only by their
concentration-dependent toxicity to mitochondria. The toxic
effects of rhodamine-123 and dequalinium chloride, two of
the most commonly used DLCs, have been linked to their ca-
pacity to inhibit the enzymes F0F1 ATPase39 and NADH-
ubiquinone reductase.40 Oral administration to mice bearing
transplanted tumours has shown that substances containing
a benzo[a]phenoxazine nucleus, such as Nile blue chloride,
exhibit a tumour-staining and growth-retarding action.41
Studies have shown that the subcellular localisation of Nile
blue chloride is highly selective to lysosomal targets and also
that cellular uptake in tumours involves an ion-trapping
mechanism.42 Also, DLCs have been shown to cause mito-
chondrial depolarisation, which leads to the opening of
mPTPC and the consequent loss of pyridine nucleotides from
the mitochondrial matrix. This effects a further increase in
mitochondrial membrane potential,43 which promotes the in-
flux of DLCs into cancer cells. Such cells exhibit mitochon-
drial abnormalities that include progressive swelling, disrup-
tion of the mitochondrial cristae, concomitant mitochondrial
outer membrane rupture and multiple mitochondrial lesions,
which ultimately result in cell death.44
Boronated DLCs
Although DLCs are promising carriers for the selective tag-
ging of 10B to mitochondria of cancer cells, there are very few
literature examples of synthetic compounds that combine
boronated entities with DLC moieties such that their corre-
sponding therapeutic effect and targeting specificity are com-
bined in a single molecular structure.
Adams et al.45 synthesised a carboranyl derivative of
dequalinium (DEQ-B), which has been shown by in vitro eval-
uations to exhibit tumour uptake and toxicology that are sim-
ilar to those characterising its non-boronated analogue. In
vitro, DEQ-B was seen to be taken up and retained by KB,
F98, and C6 tumour cell lines, but not by the normal epithe-
lial cell line CV1. At low concentrations, DEQ-B was shown to
be less toxic towards the latter cell line. The uptake, retention
and toxicity of DEQ-B were found to be comparable with
those of other non-boronated DLCs, such as dequalinium
chloride, rhodamine 123 and tetraphenylphosphonium chlo-
ride.45 Another example of a boronated DLC derivative is rho-
damine B-phenyl boronic acid (containing a single 10B atom
per molecule), which has been employed as a fluorescent
marker and has been shown to accumulate selectively in co-
lon carcinoma cells at a cancer/normal cell ratio of 5.5.46
Calabrese et al.47 reported the synthesis of a series of com-
pounds in which carboranes are combined with DLCs. A
Fig. 2 Typical delocalized lipophilic cations (DLCs): rhodamine-123
chloride, nile blue chloride, dequalinium chloride and
tetraphenylphosphonium chloride.
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preliminary in vitro evaluation study, utilising human pros-
tate carcinoma (PC3) and normal (PNT2) epithelial cell lines,
indicated the combined propensity of these agents to target
tumour cells and to deliver therapeutically relevant quantities
of boron.48 Consistent with the increased mitochondrial
membrane potential of carcinoma cells, the percentage of 10B
taken up by PC3 cells was higher than that determined in
parallel experiments involving PNT2 cells. The data indicated
that, with the exception of one Nile blue derivative, the syn-
thesized compounds exhibited features such as uptake effi-
ciency, tumour selectivity and capability to deliver therapeuti-
cally relevant amounts of boron that are pre-requisite to
candidate materials for BNCT of cancer. Fig. 3 presents the
structures of compounds selected for further evaluation.10
Rendina et al.48 reported the synthesis of closo-carborane
phosphonium salt derivatives and commented on the ab-
sence of a covalent bond between the anionic boron entity
and the cation in the compounds reported by Calabrese
et al.47 In vitro boron uptake studies have shown48 that ad-
vantageous cancer/healthy cell distribution ratios and overall
levels of boron accumulation can be achieved irrespective of
the presence or absence of a covalent bond between the
carborane and DLC moieties. Hence, it appears that a cova-
lent link between the DLC and the boron moiety may not be
necessary for the selective delivery of boron to tumour sites.49
Towards a preliminary assessment of the effects of DLC-
carboranes on cell growth,49 U-87 MG cells were incubated
over a specified time period with systematically varied con-
centrations of bis-nido-carborane dequalinium salt (BOR4).
Cell viability data (Fig. 4) demonstrated a concentration-
dependent toxicity effect and allowed the estimation of IC50
of this molecule at 0.832 μM. Analogous experiments with
carborane-loaded PC and DMPC liposomes over the boron
concentration range 0.2–4.0 μM indicated the biocompatibil-
ity of these formulations at boron concentrations of the order
of ≤2.0 μM boron. A recent study has investigated the phar-
macological behavior of BOR, BOR2, BOR3, BOR4 and BOR5
in malignant, cancer stem and normal cell lines. The work
identified selective cytotoxic behavior towards tumor cells
and cancer stem cells, while normal cells were seen to reca-
pitulate their physiological proliferation rate upon removal of
the DLC-carborane from cultures.10 Tested against the crite-
rion of selective cytotoxicity behavior, the same study identi-
fied BOR2 and BOR3 as the most promising candidate mate-
rials for further investigation.10
Discussion and conclusions
While limited, studies to date show the promise of DLC-
carboranes to act as BNCT agents that target cancer and pri-
mary GBM CSCs in the presence of normal cells with a high
degree of selectivity.10,48 Complementary work10 has further
revealed the capability of DLC-carboranes to effect growth in-
hibition in primary GBM CSCs (Fig. 5).
Fig. 3 DLC-functionalised carboranes: triphenyl methylenecarboranyl
phosphonium bromide (BOR2) and nido-carborane salts of tetraphenyl
phosphonium (BOR3), dequalinium (BOR4) and rhodamine-B (BOR5).
Fig. 4 (A) Cell growth (U-87 mg) as a function of the concentration of
bis-nido-carborane dequalinium salt (48 h incubation); (B) cell viability
after 48 h of incubation with boron-loaded PC or with boron-loaded
DMPC liposomes; error bars are mean ± sd (n = 3).
MedChemCommReview
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
O
ct
ob
er
 2
01
6.
 D
ow
nl
oa
de
d 
on
 2
4/
11
/2
01
6 
14
:2
9:
51
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Med. Chem. Commun.This journal is © The Royal Society of Chemistry 2016
Underpinned by the principle that the elimination of CSCs
may lead to positive long-term clinical outcomes,50,51 DLC-
carboranes offer the potential for selective cytotoxicity within
heterogeneous tumour cell populations. It has been shown
that the mechanism of action of DLC-carboranes involves ac-
tivation of the p53/p21 gene axis. It appears that the selective
accumulation of DLC-carboranes to the mitochondria of tu-
mour cells provides the stimulus that ultimately activates the
tumour suppressor protein p53, which mediates the DNA
damage-induced checkpoint mechanism through the trans-
activation of growth inhibitory genes, such as p21. This in
turn causes permanently malignant cells to enter a phase of
p53-dependent G1 growth arrest, and prevents cell cycling
and division. Notably, it has been shown that malignant cells
exposed to DLC-carboranes simultaneously activate the ex-
pression of genes that are linked to apoptosis (e.g. bax, bad,
caspases 3 and 9), to survival (e.g. bcl-2) and to mitogenesis
(e.g. c-myc, cyclin D1, cdk4).10 The opposing cellular response
functions in the observed gene expression profile may be
explained in terms of an attempt by cells to overcome the
DLC-carborane-triggered cell-cycle arrest mediated by p53/
p21 through genetic manipulation.
Evidence to date suggests that DLC-carboranes may be of
value not only to BNCT but also as stand-alone anticancer
drugs. Consequently, DLC-carboranes represent a new class
of anticancer agents, the pharmacological efficacy and safety
profiles of which merit investigation with reference to their
chemical structure such that the most promising compounds
are identified for clinical verification. In terms of chemistry,
the significance of the nature of the bond that connects the
DLC and carborane moieties needs to be understood in order
to allow the research focus to shift to ionic or covalent struc-
tures according to their promise to meet the performance re-
quirements imposed by the BNCT protocol.
Fig. 5 The effect of DLC-carboranes on the levels of the proliferation marker Ki-67 in primary GBM CSCs. EGFRneg primary GBM CSCs were each
treated for 24 h (left) or 48 h (right) with the IC50 concentrations of BOR3 (7 × 10
−7 m) or BOR4 (6 × 10−7 m). Panels A and B, untreated (control)
cultures; panels C and D, BOR3-treated cultures; panels E and F, BOR4-treated cultures; panels A, C and E, DAPI-stained cell nuclei; panels B, D
and F, Ki-67 expression levels; panel G, quantification of Ki-67 by means of the data obtained from panels B, D and F. The results are presented as
a percentage of the Ki-67 expression determined for untreated control cultures and represent the mean (±sd) of two independent experiments.
Statistical analysis was performed using paired t-test (p < 0.05).
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